Systemic Candidiasis – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033
Systemic candidiasis, also called acute disseminated candidiasis, is a type of fungal infection caused by species of Candida. It is characterized by the presence of Candida in ordinarily sterile sites such as blood, pleural fluid, and peritoneal fluid. It can result in various symptoms, including fever, hypotension, and leukocytosis. The most common cause of systemic candidiasis is candidemia, which occurs when Candida enters the bloodstream. This type of infection is particularly prevalent among hospitalized individuals in high-income countries. It can affect multiple organ systems, including the retina, kidney, liver, spleen, bones, and central nervous system. Chronic disseminated candidiasis is associated with liver or spleen involvement and often occurs in individuals recovering from chemotherapy-induced neutropenia. Diagnosis of systemic candidiasis can be challenging, mainly when Candida is not in the bloodstream. Treatment typically involves the administration of oral or intravenous antifungal medications.
- In the USA, the estimated incidence of candidemia was approximately 9 cases per 100,000 individuals.
Thelansis’s “Systemic Candidiasis Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Systemic Candidiasis treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights of Systemic Candidiasis across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Systemic Candidiasis Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment